Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q2 2013 · 10-Q
Revenue$1.04M$1.04M+0.2% vs Q2 2012 Net Income-$7.55M-$7.55MN/M vs Q2 2012 EPS Diluted-$0.14-$0.14N/M vs Q2 2012 Gross Profit$1,035,514+9.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,443,557N/M Free Cash Flowderived-$7,682,553N/M Margins · derivedGross margin100.0%+8.1 pt vs Q2 2012
Operating margin-783.8%−195.7 pt vs Q2 2012
Net margin-729.1%−201.1 pt vs Q2 2012
ended Jun 30, 2013 · filed Aug 9, 2013 · 40 d after period end